Soft tissue sarcoma - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Soft Tissue Sarcoma – Comprehensive Patient Guide

Soft Tissue Sarcoma – A Complete Patient Guide

Overview

Soft tissue sarcoma (STS) is a group of rare cancers that develop in the muscles, fat, fibrous tissue, blood vessels, or other supporting (connective) tissues of the body. More than 50 histologic sub‑types are recognized, each with slightly different behavior and treatment response.

  • Incidence: About 13,000 new cases of soft‑tissue sarcoma are diagnosed in the United States each year, representing roughly 1 % of all adult cancers.1
  • Age: Although STS can occur at any age, the median age at diagnosis is 55–60 years. Some sub‑types (e.g., rhabdomyosarcoma) are more common in children.
  • Gender: Slight male predominance (≈55 % male).
  • Location: Most common in the extremities (≈60 %), followed by the trunk, retroperitoneum, and head/neck.

Because STS is rare and often presents as a painless lump, many patients experience a delay in diagnosis. Early recognition and prompt specialist referral are crucial for the best outcomes.

Symptoms

Symptoms vary by tumor size, depth, and location. The following list includes the most frequent presentations:

Local (tumor‑related) symptoms

  • Painless, enlarging mass: The most common sign; often felt under the skin or deeper in the muscle.
  • Pain or tenderness: May develop as the tumor compresses nerves or surrounding structures.
  • Swelling or a feeling of fullness: Especially in the thigh, arm, or abdomen.
  • Visible bulge or skin changes: Skin may become puckered, stretched, or develop a bruise‑like discoloration.
  • Restricted movement: When a tumor is near a joint or within a limb, it can limit range of motion.

Systemic symptoms (more common with large or metastatic disease)

  • Unexplained weight loss
  • Fatigue
  • Fever or night sweats
  • Shortness of breath (if lung metastases are present)
  • Abdominal pain or distention (retroperitoneal tumors)

Any new, persistent lump that grows over weeks to months warrants medical evaluation, even if it isn’t painful.

Causes and Risk Factors

In most patients, the exact cause of soft tissue sarcoma is unknown. However, several risk factors have been identified:

Genetic and hereditary factors

  • Inherited cancer syndromes: Li-Fraumeni syndrome (TP53 mutation), neurofibromatosis type 1, hereditary retinoblastoma, and familial gastrointestinal stromal tumor syndrome increase STS risk.
  • Specific chromosomal translocations: Certain sub‑types (e.g., synovial sarcoma) are associated with characteristic gene fusions.

Environmental exposures

  • Radiation therapy: Prior therapeutic radiation for another cancer raises the risk, typically after a latency of 5–10 years.
  • Chemical agents: Long‑term exposure to vinyl chloride, dioxin, herbicides (e.g., phenoxyacetic acids), and some chemotherapy drugs (e.g., alkylating agents) have been linked to STS.

Other factors

  • Chronic lymphedema (Stewart‑Treves syndrome)
  • Older age (risk rises after 50 years)
  • Male sex (modest increase)

Having one or more risk factors does not guarantee that a sarcoma will develop, and many patients with STS have no identifiable risk.

Diagnosis

Diagnosing soft tissue sarcoma involves a stepwise approach that combines imaging, pathology, and multidisciplinary review.

Initial clinical assessment

  • Detailed history (duration, growth rate, prior radiation, family cancer history).
  • Physical exam focusing on size, depth (superficial vs. deep), mobility, and neurovascular status.

Imaging studies

  • Ultrasound: First‑line for superficial masses; can differentiate cystic from solid lesions.
  • MRI (Magnetic Resonance Imaging): Gold standard for local staging; provides precise anatomic detail, relationship to neurovascular structures, and helps plan surgery.
  • CT scan: Used for deep pelvic or retroperitoneal tumors and for evaluating chest, abdomen, and pelvis for metastases.
  • PET‑CT: Helpful in selected cases to assess metabolic activity and detect distant disease.

Pathologic confirmation

  • Core needle biopsy: Preferred method; obtains sufficient tissue for histology, immunohistochemistry, and molecular testing.
  • Incisional or excisional biopsy: Reserved for cases where a core biopsy is nondiagnostic.
  • Pathology labs assess:
    • Histologic subtype
    • Grade (low, intermediate, high)
    • Margins
    • Specific gene fusions or mutations (e.g., SYT‑SSX in synovial sarcoma).

Staging

Staging follows the AJCC (American Joint Committee on Cancer) system, incorporating tumor size (T), nodal involvement (N), metastasis (M), and histologic grade. Accurate staging guides treatment decisions and prognosis.

Treatment Options

Treatment is individualized based on tumor size, location, grade, and whether the disease has spread. Management typically involves a multidisciplinary team (surgical oncology, medical oncology, radiation oncology, pathology, radiology, and supportive care).

Surgery

  • Goal: Achieve wide negative margins (no tumor cells at the resection edge) while preserving limb function.
  • Techniques include limb‑sparing wide excision, compartmental resections, or, when necessary, amputation.
  • Reconstruction (skin grafts, flaps, endoprosthetic implants) may be needed to restore form and function.

Radiation therapy

  • Pre‑operative (neoadjuvant) radiation can shrink tumors, making surgery easier.
  • Post‑operative (adjuvant) radiation reduces local recurrence, especially when margins are close.
  • Modalities: external beam radiation (3D‑CRT, IMRT), brachytherapy, or proton therapy for deep‑seated tumors.

Systemic therapy

  • Chemotherapy: Doxorubicin ± ifosfamide is the backbone for high‑grade or metastatic disease. Alternatives include gemcitabine‑docetaxel, trabectedin, or pazopanib (a tyrosine‑kinase inhibitor). Response rates are modest (15–30 %).
  • Targeted therapy: Pazopanib is FDA‑approved for advanced non‑adipocytic STS. For specific molecular alterations (e.g., NTRK fusions), agents like larotrectinib may be used.
  • Immunotherapy: Trials with checkpoint inhibitors (pembrolizumab, nivolumab) are ongoing; benefit appears limited to selected histologies.

Clinical trials

Because STS is rare and heterogeneous, enrollment in a clinical trial is strongly encouraged when available. Trials explore novel agents, combination regimens, and adaptive radiation techniques.

Lifestyle & supportive care

  • Maintain a balanced diet rich in protein to support wound healing.
  • Engage in gentle range‑of‑motion exercises as tolerated to preserve limb function.
  • Manage pain with acetaminophen, NSAIDs, or prescribed neuropathic agents.
  • Psychological support (counseling, support groups) is essential.

Living with Soft Tissue Sarcoma

Living with STS involves ongoing medical follow‑up and day‑to‑day self‑care.

Follow‑up schedule

  • First 2–3 years: Physical exam and imaging (MRI of primary site, chest CT) every 3–6 months.
  • Years 3–5: Every 6–12 months.
  • After 5 years: Annual visits, unless symptoms dictate earlier imaging.

Rehabilitation

  • Physical therapy to improve strength and flexibility after surgery or radiation.
  • Occupational therapy for activities of daily living, especially after limb‑sparing procedures.

Managing side effects

  • Radiation dermatitis: Keep the area clean, apply prescribed moisturizers, avoid sun exposure.
  • Chemotherapy‑related fatigue: Prioritize rest, short naps, and light activity.
  • Lymphedema: Elevation, compression garments, and manual lymphatic drainage when indicated.

Emotional well‑being

Connecting with sarcoma‑specific organizations (e.g., Sarcoma Alliance for Research through Collaboration, Soft Tissue Sarcoma Foundation) provides peer support, education, and advocacy resources.

Prevention

Because most soft tissue sarcomas have no clear cause, primary prevention is limited. However, the following measures may lower risk:

  • Avoid unnecessary ionizing radiation; discuss the risks/benefits of diagnostic imaging that involves radiation.
  • Follow occupational safety guidelines to limit exposure to known carcinogens (e.g., vinyl chloride, certain herbicides).
  • Maintain a healthy lifestyle—regular exercise, balanced diet, and smoking cessation—although direct links to STS are not definitive, these habits improve overall cancer resilience.
  • For individuals with hereditary cancer syndromes, adhere to recommended surveillance programs (e.g., annual MRI of the whole body for Li‑Fraumeni patients).

Complications

If left untreated or inadequately managed, soft tissue sarcoma can lead to serious complications:

  • Local invasion: Tumor may erode bone, encase major blood vessels, or compress nerves, causing loss of function or severe pain.
  • Metastasis: Approximately 20–30 % of patients develop distant spread, most commonly to the lungs, then liver and bone.
  • Pathologic fracture: Deep or large lesions in weight‑bearing bones can weaken the structure.
  • Infection: Post‑surgical wound infections can delay healing and necessitate additional procedures.
  • Chronic Lymphedema: After extensive lymphatic removal or radiation.
  • Psychological distress: Anxiety, depression, and body‑image concerns are common, especially after limb‑altering surgery.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe pain from the tumor site that does not improve with usual pain medication.
  • Rapid swelling or a feeling of pressure in the chest, abdomen, or throat that makes breathing difficult.
  • New weakness, numbness, or loss of function in an arm or leg (possible nerve or vascular compromise).
  • Uncontrolled bleeding from the tumor or surgical wound.
  • High fever (>38.5 °C / 101.3 °F) with chills, especially if you have a recent incision or catheter.
  • Sudden onset of shortness of breath or chest pain, which could indicate lung metastasis or a pulmonary embolism.

If you are unsure, contact your oncology team promptly; early evaluation can prevent life‑threatening complications.

References

  1. Mayo Clinic. “Soft tissue sarcoma.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/soft-tissue-sarcoma
  2. National Cancer Institute. “Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version.” 2022. https://www.cancer.gov/types/soft-tissue-sarcoma/patient
  3. American Cancer Society. “Soft Tissue Sarcoma.” 2024. https://www.cancer.org/cancer/soft-tissue-sarcoma.html
  4. Cleveland Clinic. “Soft Tissue Sarcoma.” 2023. https://my.clevelandclinic.org/health/diseases/14880-soft-tissue-sarcoma
  5. World Health Organization. “Classification of Tumours of Soft Tissue and Bone.” 2020.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References